{"id":"intranasal-budesonide-spray","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Epistaxis (nosebleed)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Pharyngeal irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide binds to glucocorticoid receptors in nasal tissue, leading to decreased production of inflammatory cytokines, reduced recruitment of immune cells, and stabilization of mast cells. This results in reduced nasal inflammation, congestion, and allergic symptoms. The intranasal formulation delivers the drug directly to the site of inflammation while minimizing systemic exposure.","oneSentence":"Budesonide is a corticosteroid that reduces inflammation in the nasal airways by suppressing immune cell activation and inflammatory mediator release.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:44.273Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis"},{"name":"Nasal inflammation and congestion"}]},"trialDetails":[{"nctId":"NCT06076304","phase":"PHASE4","title":"Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis","status":"RECRUITING","sponsor":"Daniel Merenstein","startDate":"2023-11-21","conditions":"Sinus Infection, Acute Sinusitis","enrollment":3720},{"nctId":"NCT07270302","phase":"PHASE1, PHASE2","title":"Nebulized Nasal Steroids","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-12","conditions":"Chronic Rhinosinusitis","enrollment":50},{"nctId":"NCT05878093","phase":"PHASE3","title":"Dupilumab in Chinese Adult Participants With CRSwNP","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-05-16","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":63},{"nctId":"NCT06830109","phase":"PHASE2","title":"Nasal Obstruction With Oxymetazoline and Corticosteroids","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-10-15","conditions":"Nasal Obstruction","enrollment":80},{"nctId":"NCT06785662","phase":"PHASE4","title":"Budesonide Irrigation in Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Siriraj Hospital","startDate":"2025-02-12","conditions":"Allergic Rhinitis","enrollment":78},{"nctId":"NCT05325489","phase":"PHASE3","title":"Comparison of Nebulized Budesonide and Intranasal Budesonide Spray in Children With Adenotonsillar Hypertrophy","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2022-04","conditions":"Snoring, Mouth Breathing","enrollment":100},{"nctId":"NCT04132570","phase":"PHASE4","title":"A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2019-10-22","conditions":"Rhinitis","enrollment":206},{"nctId":"NCT02562924","phase":"NA","title":"The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery","status":"COMPLETED","sponsor":"University of Vermont Medical Center","startDate":"2015-11","conditions":"Chronic Sinusitis, Nasal Polyposis","enrollment":40},{"nctId":"NCT04077892","phase":"EARLY_PHASE1","title":"Compare the Effect of INS Alone and Added LTRA in Treatment of SAR","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2016-06-01","conditions":"Allergic Rhinitis","enrollment":46},{"nctId":"NCT00912171","phase":"PHASE4","title":"Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children","status":"COMPLETED","sponsor":"University of Bologna","startDate":"2009-01","conditions":"Obstructive Sleep Apnea Syndrome","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intranasal Budesonide Spray","genericName":"Intranasal Budesonide Spray","companyName":"Second Xiangya Hospital of Central South University","companyId":"second-xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide is a corticosteroid that reduces inflammation in the nasal airways by suppressing immune cell activation and inflammatory mediator release. Used for Allergic rhinitis, Nasal inflammation and congestion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}